Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa.

Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Neuroendocrinol Lett. 2002.

Organ: retina-vision · Type: clinical · Peptides: Epitalon

PMID: 12195242

Combined Campbell-rat and human report on Epitalon in pigmentary retinal degeneration; the authors claim a positive clinical effect in 90% of treated patients — a 2002 communication, not a modern multicenter RCT.

Editorial summary of a 2002 original article in Neuroendocrinology Letters. PubMed indexes the paper as a controlled clinical trial. Animal plus human work. Public pages cite PubMed only. Read the paper: PMID 12195242.

Methods

The authors studied tetrapeptide Epitalon (Ala-Glu-Asp-Gly) in congenital pigmented degeneration of the retina. One arm is Campbell rats; the other is patients with degenerative retinal lesions. The English abstract does not give sample size, dose, duration, or how patients were allocated. Those details belong in the primary text. This page does not reprint the publisher PDF.

Findings

In Campbell rats, Epitalon is reported to intensify bioelectric and functional activity of the retina by preserving morphological structure. In patients with degenerative retinal lesions, the authors report a positive clinical effect in 90% of cases. They suggest the tetrapeptide participates in transcription mechanisms common to the epiphysis and the retina.

The 90% figure is the authors’ clinical impression in this 2002 communication. Independent replication and later controlled evidence are separate questions. It is not a current treatment guideline. Follow the PMID.